Target intelligence / Profile preview

DNA topoisomerase

Molecular classification
Enzyme, Type I topoisomerase (subfamily), Type II topoisomerase (subfamily)
01

Overview

DNA topoisomerases are essential enzymes that regulate the overwinding or underwinding (“supercoiling”) of double-stranded DNA. They solve critical topological problems during fundamental cellular processes such as replication, transcription, recombination, chromosome condensation/segregation, and chromatin remodeling. These enzymes function by introducing temporary single-strand breaks (type I) or double-strand breaks (type II) into the phosphodiester backbone of DNA. This allows them to relax supercoils, untangle knots/catenanes formed during replication or repair processes, and ensure proper chromosome segregation. There are two main classes—Type I enzymes cleave one strand at a time without ATP hydrolysis; Type II cleave both strands using ATP energy. Human isoforms include TOP1/TOP2A/TOP2B; bacterial forms include gyrases which introduce negative supercoils. Because their activity is vital for rapidly dividing cells—and because their inhibition leads to lethal genome damage—DNA topoisomerases are validated therapeutic targets in cancer chemotherapy and antibacterial drug development.[1][2][4][5][6]

Other names
TopoisomeraseDNA topoisomerase IDNA topoisomerase IITopo ITopo IIGyrase (for bacterial type II)Reverse gyrase (archaeal)
02

Mechanism of action

– Inhibitors can stabilize the transient break in the DNA introduced by the enzyme, preventing religation and leading to accumulation of breaks that trigger cell death. – Some drugs act as poisons by trapping the enzyme-DNA cleavage complex; others inhibit catalytic activity or prevent binding to DNA.[6]

03

Biological functions

Regulation of DNA topologyRelaxation of supercoiled DNADecatenation of intertwined DNA molecules after replicationFacilitation of DNA replication, transcription, recombination, and chromatin remodeling[1][2][4][5]
04

Disease associations

Cancer[6]Infection (bacterial targets for antibiotics)
05

Safety considerations

– Myelosuppression and secondary malignancies with some inhibitors due to off-target effects on normal proliferating cells.– Risk of genotoxicity from accumulation of double-strand breaks.
06

Interacting drugs

Camptothecin and derivatives (topotecan, irinotecan) – target type I[6]

2 more in the full profile.

07

Biomarkers

– Overexpression or mutation status may be used as a biomarker in certain cancers for patient selection or monitoring response to therapy.

Beyond the preview

Go deeper on DNA topoisomerase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA topoisomerase.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call